X4 Pharmaceuticals Inc (XFOR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.040.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XFOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 185.1% |
| Our one-year growth estimate | diamond | 22.9% |
Growth built into the price is above our model estimate.
The price assumes 162.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
XFOR — CFO transition
Dated 2026-07-01
Class II director — Kelly Gold: Appointment of Kelly Gold as a Class II director and increase in the board size from five to six directors.
Why it matters: Finishing enrollment is key for getting mavorixafor approved. This shows they are making progress.
Supportive ifEnrollment for the pivotal Phase 3 trial is completed by the end of Q3 2026.
Worry ifEnrollment is not completed by the end of Q3 2026.
Why it matters: Revenue growth trends will show if the company is on track to meet its financial goals. It reflects overall business health.
Watch forQ2 2026 earnings report shows revenue growth above $2.5M.
Also watch forQ2 2026 earnings report shows revenue growth below $2.5M.
Why it matters: If sector growth speeds up, it could benefit X4. A strong sector can lift individual stocks.
Supportive if3-year revenue growth in the sector exceeds 12%.
Worry if3-year revenue growth in the sector drops below 8%.
Why it matters: Finishing enrollment is key for mavorixafor's growth. This trial is important for approval.
Supportive ifEnrollment in the 4WARD trial is completed by the end of Q3 2026.
Worry ifEnrollment is not completed by the end of Q3 2026.
Why it matters: Completing enrollment is key for growth. It shows the company is on track with its plans.
Supportive ifEnrollment is completed by the end of Q3 2026.
Worry ifEnrollment is not completed by the end of Q3 2026.
Why it matters: Saving costs is important for better financial health. It shows how well the company runs.
Supportive ifX4 reports saving over $13M each year.
Worry ifNo progress is reported toward the $13M cost savings target.
Why it matters: The launch of mavorixafor is critical for X4's growth. Delays could impact investor confidence.
Supportive ifManagement confirms plans to launch mavorixafor by the end of 2028.
Worry ifManagement delays the launch timeline beyond the end of 2028.
Why it matters: Achieving cost savings is vital for improving financial health. Failure to meet this target could raise concerns.
Supportive ifThe company says it has saved at least $13 million each year.
Worry ifNo major cost savings have been reported. Operating losses are still happening.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$208 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $665 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,356 loss on $10,000 · 33.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.